Skip to main content

These 12 companies see profit growth of more than 500% over last 5 fiscal years

Privi Speciality Chemicals, Ipca Laboratories and Astrazeneca Pharma India are among the 12 names

Increasing profit is a sign of a healthy balance sheet for any company. 12 companies from the BSE universe saw an increase in profit every year and over the last five fiscal years, their profits jumped more than 500% each. We considered companies with a market cap of over Rs 500 crore. The share price of these companies at least doubled in the last 5 years. (Data Source: ACE Equity).



Privi Speciality Chemicals | During the FY16-FY20 period, the company saw profit growth of 1,564 percent to Rs 176 crore. In the last 5 years (October 20, 2015, to October 19, 2020), the stock price surged 153 percent to Rs 540 as on October 19, 2020.

Astrazeneca Pharma India  | During the FY16-FY20 period, the company saw a profit growth of 1273 percent to Rs 72 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 244 percent to Rs 4291 as on October 19, 2020.

Black Rose Industries   | During the FY16-FY20 period, the company saw a profit growth of 1186 percent to Rs 21 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 344 percent to Rs 121 as on October 19, 2020.

Chambal Fertilisers & Chemicals  | During the FY16-FY20 period, the company saw a profit growth of 1052 percent to Rs 1223 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 173 percent to Rs 162 as on October 19, 2020.

Astec Lifesciences  | During the FY16-FY20 period, the company saw a profit growth of 838 percent to Rs 48 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 331 percent to Rs 1040 as on October 19, 2020.

Mastek  | During the FY16-FY20 period, the company saw a profit growth of 728 percent to Rs 114 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 429 percent to Rs 805 as on October 19, 2020.

JK Paper  | During the FY16-FY20 period, the company saw a profit growth of 671 percent to Rs 468 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 110 percent to Rs 89 as on October 19, 2020.

Heidelberg Cement India  | During the FY16-FY20 period, the company saw a profit growth of 657 percent to Rs 268 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 126 percent to Rs 186 as on October 19, 2020.

Shivalik Rasayan  | During the FY16-FY20 period, the company saw a profit growth of 600 percent to Rs 22 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 981 percent to Rs 432 as on October 19, 2020.

ADF Foods  | During the FY16-FY20 period, the company saw a profit growth of 547 percent to Rs 43 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 341 percent to Rs 408 as on October 19, 2020.

Gujarat Gas  | During the FY16-FY20 period, the company saw a profit growth of 538 percent to Rs 1199 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 197 percent to Rs 289 as on October 19, 2020.

Ipca Laboratories  | During the FY16-FY20 period, the company saw a profit growth of 536 percent to Rs 611 crore. In the last 5 years (October 20, 2015 to October 19, 2020), the stock price surged 174 percent to Rs 2095 as on October 19, 2020.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more